• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Myobloc

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Myobloc

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Myobloc, a sterile liquid formulation of purified neurotoxin, has been approved as an injectable solution for the treatment of abnormal head position and neck pain associated with cervical dystonia. Myobloc is available in three vial configurations of 2500 Units, 5000 Units, and 10000 Units, offering convenience and flexibility for dosing.

    Cervical dystonia, also known as spasmodic torticollis, is a neurological disorder that affects the cervical area of the spine. It causes the neck and shoulder muscles to contract involuntarily, resulting in painful muscle spasms that often make daily functioning difficult. Myobloc is the first FDA approved drug for treatment of cervical dsytonia.

    Clinical Results

    Myobloc has been evaluated in two phase III studies involving a total of 186 adult subjects. The primary efficacy outcome of the trials was the Toronto Western Spasmodic Torticollis Rating Scale, which examines the severity of abnormal head position, the severity and duration of pain, and the disabiling effects placed on the person's activities. Subjects were randomized to receive placebo, 5000 Units, or 10000 Units in single treatment sessions and were evaluated for 16 weeks following injection.

    There were no statistically significant differences between the 5000 U and the 10000 U doses. Most subjects who reported improvements after four weeks had returned to their baseline status by the end of the 16 weeks. Subjects in the two treatment groups did experience decreases in pain, though many also reported increases in symptoms regardless of receiving treatment or placebo.

    Side Effects

    Adverse events associated with the use of Myobloc may include (but are not limited to) the following:


    • Dry mouth
    • Dysphagia
    • Injection site pain
    • Dyspepsia
    • Headache

    Mechanism of Action

    Botulinum Toxin Type B is a sterile liquid formulation of a purified neurotoxin that acts at the neuromuscular junction to produce flaccid paralysis. The solution is injected directly into the muscle.

    Additional Information

    For additional information on Myobloc, please visit Myobloc.

    Approval Date: 2000-12-01
    Company Name: Elan Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing